Study wrapper · #897
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
Lee HM, Marakkalage KG, Kim SH, et al. International journal of obesity (2005). 2026.
DOI: 10.1038/s41366-026-02161-9PubMed: 42457940
Editor's note
This is a mouse study whose primary subject is vutiglabridin, a novel oral compound, with semaglutide serving as the comparator and combination partner. The reported signal is that adding vutiglabridin was associated with overcoming the weight-loss plateau seen with semaglutide alone. As preclinical animal work, it offers mechanistic direction only and does not speak to outcomes in people.
Plain-language abstract
In obese mice, the investigational small molecule vutiglabridin was studied alongside semaglutide and other GLP-1 receptor agonists, where it was associated with continued fat loss past the point where semaglutide's effect leveled off and with less weight regain after semaglutide was stopped.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026